Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02623426) enrolled 194 people across three groups. Each group received a different treatment injected into the eye for a condition affecting the retina: 65 people received a dexamethasone pellet (Ozurdex), 65 received methotrexate, and 64 received ranibizumab (Lucentis). The trial was measuring changes in the thickness of a specific layer at the centre of the retina — called the central subfield — using eye-scanning technology, comparing thickness at the start of the trial to thickness at 12 weeks. Most participants completed the study, with only a small number (1–3 per group) not finishing. The reported data shows the primary outcome as a proportion — that is, a fraction of the original retinal thickness measured at the start. A number below 1.0 means the retina appeared thinner at 12 weeks compared to the start, with lower numbers representing a greater reduction in thickness. According to the results reported on ClinicalTrials.gov, at 12 weeks the dexamethasone group had a reported proportion of 0.65 (meaning the retina measured about 65% of its original thickness), the methotrexate group had a proportion of 0.88 (about 88% of original thickness), and the ranibizumab group had a proportion of 0.79 (about 79% of original thickness). No other outcome measures were included in the submitted results data. Data on secondary outcomes, if any were collected, was not reported in the structured results available. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37318415) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have non-infectious uveitis (inflammation inside the eye) that is inactive or only very mildly active, and has been that way for at least 4 weeks
- You have swelling in the central part of your retina (called macular edema), confirmed by a specific eye scan, that developed after receiving a steroid injection into the eye
- You have had a specific eye imaging test (fluorescein angiogram) that gives clear enough results to measure fluid leakage in the centre of your eye
- Your vision in the affected eye is at least 5/200 (some ability to see, even if limited)
- Your eye pressure is within a specific range (between 5 and 21 mmHg), with or without up to 3 pressure-lowering eye drop medications or previous glaucoma surgery
- The inside of your eye is clear enough to allow scanning and examination
Who may not be able to join:
- You have a history of infectious uveitis (eye inflammation caused by infection) in either eye
- You have a history of infectious scleritis (infection-related inflammation of the white of the eye) in either eye
- You have a history of corneal infection (keratitis), unless it was caused by dry eye, in either eye
- You have a history of central serous retinopathy (a condition where fluid builds under the retina) in either eye
- You currently have an active eye infection (conjunctivitis) in either eye
- You are taking more than 10 mg per day of oral prednisone (or an equivalent steroid), or your current lower dose has not been stable for at least 4 weeks
- You are taking immune-suppressing medications that have not been at a stable dose for at least 4 weeks (methotrexate is allowed if the dose has been stable for 4 weeks)
- You are currently taking acetazolamide or a similar oral medication for eye pressure
- You have a known allergy or sensitivity to any ingredients in the study medications
- You are pregnant, breastfeeding, have a positive pregnancy test, or are unwilling to use reliable contraception throughout the trial (if you are a woman who could become pregnant)
- You have a history of a serious eye infection inside the eye (infectious endophthalmitis)
- You have severe glaucoma with significant damage to the optic nerve
- You have had active non-infectious scleritis in the past 12 months
- You have scar tissue on the surface of your retina (epiretinal membrane) that the study doctor believes could prevent the swelling from improving
- You have a torn or damaged lens capsule in the eye
- You have silicone oil present in the eye
- You received a dexamethasone eye implant (Ozurdex) in the past 12 weeks
- You received certain eye injections (anti-VEGF agents, methotrexate, or steroid injections in or around the eye) in the past 4 weeks
- You have had a fluocinolone acetonide implant (Retisert) placed in the eye in the past 3 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Douglas A Jabs, MD, MBA, Center for Clinical Trials and Evidence Synthesis, JHU, Baltimore, MD
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Baseline Central Subfield Thickness Observed at 12 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.